A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Condition(s) studied

Investigational drug(s) / intervention(s)

Cagrilintide: Cagrilintide will be administered subcutaneously.

Semaglutide: Participants will recieve semaglutide subcutaneously.

Placebo cagrilintide: Participants will receive placebo matched to cagrilintide.

Placebo semaglutide: Participants will receive placebo matched to semaglutide.

Study summary

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.

Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

Eligibility

Primary outcome measure(s)

• CagriSema versus placebo: Relative change in body weight — From baseline (week 0) to end of treatment (week 68)
  Measured in percentage (%)
• CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction — From baseline (week 0) to end of treatment (week 68)
  Measured as count of participants

Trial sites (256)

+ 216 more sites — see the full list on the official registry below.